HK WHITEOAK PHARMA

海昶生物
HAICHANG BIOTECH



QTsome™-Enabled Nucleic Acid Therapeutics

HONG KONG WHITEOAK PHARMACEUTICAL CO., LTD

A SUBSIDIARY OF HAICHANG BIOTECH

APR 2025

Key Technology: Novel LNP Technology–QTsome™ for Nucleic Acid Delivery



Corona Virus
100 nm





QTsome™
100 nm



QTsome™ Advantages

HK WHITEOAK PHARMA

QTsome™

1. Physical stability is enhanced through greater electrostatic interactions
2. Efficacy and safety are validated in clinical trials
3. For i.v. route(e.g.,HC0301), selective targeting of tumor neovasculature and endothelium
4. For local route(e.g.,HC009,HC016), lymphatic targeting for enhanced immune activation and reduced systemic adverse side effects
5. QTsomes exhibit broad applicability, enabling effective delivery of both oligos (e.g., ASOs, siRNAs, miRNAs) and mRNAs.



Company Profile

HK WHITEOAK PHARMA

Zhejiang Haichang Biotech Co., Ltd.(Parent Company)

- Proprietary QTsome™ delivery platform
- Development and commercialization of nucleic acid drugs
- mRNA vaccines, oligonucleotide drugs, and high-end complex injectables
- IVT and LNP manufacturing with cGMP standards.

100+
Global R&D staff

2 Areas of Focus
- Innovative nucleic acid drugs
- Complex injectables

3+1
- 3 products in clinical stage
- 1 generic on the market

1+4
Manufacturing sites

3 Key Markets
USA, China, and Europe

2024
Expected IPO

Hong Kong WhiteOak Pharmaceutical Co., Ltd.

Hong Kong WhiteOak Pharmaceutical Company Limited is a Hong Kong SAR-based company that was officially incorporated on 21 January 2020. It is a wholly-owned subsidiary of Zhejiang Haichang Biopharmaceutical Technology Co., Ltd and a professional team comprising senior experts in the field of pharmaceuticals from China and the United States, primarily from the former U.S. FDA seniors. The team possesses a wealth of resources and a deep understanding of the innovation and development of the field of biopharma. Focus on biotechnology, new drug discovery and development, and innovative techs..

Management Team Profile

The Core Team boasts a diverse range of expertise, combining academic, industry and FDA experience.

Founder, CEO

Ben Zhao, Ph.D.

- ✓ 20+ years experience in developing global regulatory strategy solutions and nucleic acid research
- ✓ Former FDA Level III Inspector and CMC senior reviewer specialized in complex injectables at the CDER of US FDA
- ✓ 12 Patents inventor, developed the first generic liposomal doxorubicin (Libaoduo®) in 2008 and nanoparticle albumin-bound paclitaxel (Apexelsin®) in 2024

Co-CEO

Xiaofeng Meng Ph.D.

- ✓ Chairman of Epic Pharma (US)
- ✓ Expert in complex formulation: Led the launch of several new drugs and more than 100 generic drugs in Europe and the United States



Chief Scientist

Robert J. Lee, Ph.D.

- ✓ Kimberly professor of Pharmaceutics at Ohio State University
- ✓ Endocyte, Genemedicine
- ✓ Expert in liposome / nanoparticle delivery systems, targeted delivery systems, non-viral gene delivery systems, small nucleic acid delivery systems

Chief Medical Officer

Angela Men, M.D., Ph.D.

- ✓ 17+ years of experience in evaluating submissions for Neurology and Oncology products at US FDA
- ✓ Skilled in designing phase I-IV clinical /clinical pharmacology trials PI and Phase I trials in US and China
- ✓ Ph.D., in Pharmaceutical Science from Virginia Commonwealth University; M.D. from Tianjin Medical University

Haichang Biotech Development

HK WHITEOAK PHARMA

2008
Liposome Doxorubicin launched in China

2013
HCBio established

2014
R&D team and early lab established

2016
Pilot-scale test lab for complex formulations established

2017
Completed Pre-A financing

2018
Completed series A financing
Collaborated with Rexahn on HC0301

2019
HC007 License-out with DRL

2020
Acquisition of The WhiteOak Group, Inc.
Completed A+ financing

2021
Completed series B financing
HC007 License out – Kexing Pharma
HC008 Joint venture Haihekang Pharma
HK & EU subsidiaries established

2022
Completed B+ financing
HC0301 commenced Phase I clinical trials
HC009 mRNA vaccine received US/China IND clearance

2023
HC0301 was granted orphan drug destination from US FDA
HC007 was approved in China

2024
Completed series C financing
HC007 launched in EU
HC0301 entered Phase II
HC016 IND cleared

R&D Pipelines

HK WHITEOAK PHARMA

Nucleic Acid Drug Pipeline

Project Type	Project Code	Targets	Indications	Preclinical	IND	Phase I	Phase II	Phase III
Nucleotide drugs	★HC0301	AKT-1	Hepatocellular carcinoma					
	HC0201	AKT-1	Renal cell carcinoma					
	HC016	TLR9	Head & neck cancer, Melanoma					
	HC-APOC3	APOC3	Hyperlipidemia					
	HC009	Booster	mRNA vaccine					

High-end Complex Injection Pipeline

Project Type	Project code	Reference Products	Indications	Tech Development	Process Validation	BE Study	ANDA
High-end complex injection	★HC007	Abraxane®	Lung cancer; breast cancer; pancreatic cancer etc.				
	HC006	Onivyde®	Pancreatic cancer				
	HC008	Exparel®	Postoperative anesthesia; nerve-blocking analgesia				
	HC004	Ambisome®	Fungal infection				

Contact Us

海昶生物
HAICHANG BIOTECH

HK WHITEOAK PHARMA

11/F, Block A, Lakeside Centre, No. 837 Jinsha Avenue,
Xiasha Street, Qiantang District,
Hangzhou, Zhejiang, China
0571-26262031

Unit 105,1/F, Building 5E, Phase One,
Hong Kong Science Park,
Pak Shek Kok, New Territories, Hong Kong
+852 2669 8880